Pull to refresh
Logo
TRI launches TRIAL.OS, an AI operating system for clinical trials

TRI launches TRIAL.OS, an AI operating system for clinical trials

New Capabilities

Pay-per-use apps aim to bring AI-augmented risk monitoring to any company running a trial

Today: TRI launches TRIAL.OS, AI operating system for trials

Overview

Updated 1 hour ago

A Cambridge, England company has launched what it calls an operating system for intelligent clinical trials. TRIAL.OS uses AI to draft the risk assessments and monitoring plans that study teams have historically built by hand over weeks.

Read a trial protocol into the system, and it produces a structured risk framework in hours. Every output is a draft that study teams review and own — the machine advises, humans decide.

Why it matters

If AI-augmented risk monitoring takes hold, trials start faster and run safer, cutting years and millions off drug development.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

500+
Clinical trials run on OPRA
More than 500 global trials have used TRI's existing risk-based quality management platform.
6
Core functions of TRIAL.OS
Understand, predict, explain, recommend, automate, and learn.
13
Years TRI has spent in trial quality management
The company has focused on risk-based quality management since its founding.
30%
Claimed reduction in monitoring costs
TRI says risk-directed monitoring and automated checks can lower monitoring costs by up to 30 percent.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

2016 October 2026

4 events Latest: Today
Tap a bar to jump to that date
  1. TRI launches TRIAL.OS, AI operating system for trials

    Today Product

    The six-function system (understand, predict, explain, recommend, automate, learn) sells as pay-per-use apps, standalone or atop OPRA.

  2. ICH finalizes updated good clinical practice guideline E6(R3)

    Regulatory

    The updated guideline emphasizes risk-based quality management across the trial lifecycle, setting the standard TRIAL.OS is built against.

  3. TRI adds Risk Assessment and Management module

    Product

    The module lets sponsors define critical-to-quality factors and build risk plans inside OPRA.

  4. TRI launches Centralized Monitoring service

    Product

    TRI begins offering centralized monitoring for clinical trials, laying the foundation for its risk-based platform.

Scenarios

1

TRI names its first pharmaceutical customers for TRIAL.OS

Likely Resolves by Q2 2027

Discussed by: TRI's launch materials and clinical trial trade press (Applied Clinical Trials, Clinical Leader)

TRI says it built TRIAL.OS with customers running the apps against their own protocols. If those pilots convert, TRI will name sponsors or contract research organizations using the apps in production trials. That would validate the pay-per-use model and show real demand beyond early adopters.

2

Rivals ship comparable AI risk-assessment tools

Possible Resolves by Oct 13, 2027

Discussed by: Industry analysts covering RBQM platforms (Medidata, Veeva, Octalsoft among incumbents)

Medidata, Veeva and Octalsoft already sell clinical trial risk tools. If TRIAL.OS gains traction, expect competitors to add AI-drafted risk frameworks and guided monitoring to their offerings. The open questions are how fast they move and how closely their features match TRIAL.OS.

3

FDA or EMA issues guidance on AI-generated trial risk tools

Unlikely Resolves by Oct 13, 2027

Discussed by: Clinical trial compliance specialists and regulatory observers

TRIAL.OS outputs are drafts reviewed by humans, and TRI says the system aligns with the EU AI Act. Regulators may still want to see how AI-generated risk frameworks hold up across studies. A formal guidance or a pattern of inspection findings would set the compliance baseline for the whole category.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

Early-to-mid 2000s

Electronic Data Capture replaces paper case report forms (2000s)

Clinical trials ran on paper case report forms that staff transcribed by hand, a slow and error-prone process. Electronic data capture systems digitized the workflow, letting teams collect and check data in near real time.

Then

Data entry errors fell and trials could be monitored continuously rather than at the end.

Now

EDC became the standard infrastructure for global trials, proving that digital tools could replace manual oversight at scale.

Why this matters now

TRIAL.OS is attempting the same kind of shift for risk management — replacing manual, expert-heavy assessments with software that learns from the data.

2013

FDA guidance on risk-based monitoring (2013)

The FDA issued draft guidance urging sponsors to move away from 100 percent source data verification toward risk-based monitoring that focuses checks where risk is highest.

Then

The industry began adopting risk-based quality management practices.

Now

It set the regulatory foundation for platforms like OPRA, and TRIAL.OS layers AI on top of that same risk-based framework.

Why this matters now

TRI built OPRA on this regulatory opening; TRIAL.OS is the AI generation of the same idea.

Sources

(4)